This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

A woman walks down Wall Street in New York City, U.S., April 8, 2025. REUTERS/Kylie Cooper/File Photo A heavy slate of U.S. company results in the coming week will test a stock market shaken by a ...